Skip to main content

Table 1 Antimalarial drug-resistance mutations in the pre-treatment and post-treatment samples

From: Dynamic changes in genetic diversity, drug resistance mutations, and treatment outcomes of falciparum malaria from the low-transmission to the pre-elimination phase on the islands of São Tomé and Príncipe

Antimalarial drug-resistance markers Pre-treatment
(n = 60)
Post-treatment
(n = 51)
Total
(n = 111)
  No. (%) No. (%) No. (%)
pfmdr1 86    
N 8 (13.3) 10 (19.6) 18 (16.2)
Y 52 (86.7) 14 (78.4) 92 (82.9)
N/Y 0 (0.0) 1 (2.0) 1 (0.9)
pfmdr1 184    
F 41 (68.3) 28 (54.9) 69 (62.2)
Y 19 (31.7) 23 (45.1) 42 (37.8)
pfmdr1 1246    
D 58 (96.7) 49 (96.1) 107 (96.4)
Y 2 (3.3) 2 (3.9) 4 (3.6)
pfcrt 76    
K 1 (1.7) 5 (9.8) 6 (5.4)
T 59 (98.3) 44 (86.3) 103 (92.8)
K/T 0 (0.0) 2 (3.9) 2 (1.8)
pfmdr1 86 + 184 + 1246-pfcrt 76    
YFD-T 33 (55.0) 24 (47.1) 57 (51.4)
YYD-T 16 (26.7) 14 (27.5) 30 (27.0)
NFD-T 6 (10.0) 3 (5.9) 9 (8.1)
YFD-K 2 (3.3) 1 (2.0) 3 (2.7)
NYD-K 0 (0.0) 3 (5.9) 3 (2.7)
YYY-T 1 (1.7) 1 (2.0) 2 (1.8)
NYD-K/T 0 (0.0) 2 (3.9) 2 (1.8)
NYD-T 1 (1.7) 1 (2.0) 2 (1.8)
NYY-T 1 (1.7) 1 (2.0) 2 (1.8)
N/YYD-K 0 (0.0) 1 (2.0) 1 (0.9)